95 related articles for article (PubMed ID: 19566854)
21. Evaluation of glucose response to 3 types of insulin using a continuous glucose monitoring system in healthy alpacas.
Byers SR; Beemer OM; Lear AS; Callan RJ
J Vet Intern Med; 2014; 28(5):1613-20. PubMed ID: 24965884
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
Gedulin BR; Smith PA; Jodka CM; Chen K; Bhavsar S; Nielsen LL; Parkes DG; Young AA
Int J Pharm; 2008 May; 356(1-2):231-8. PubMed ID: 18291606
[TBL] [Abstract][Full Text] [Related]
23. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
Mari A; Nielsen LL; Nanayakkara N; DeFronzo RA; Ferrannini E; Halseth A
Horm Metab Res; 2006 Dec; 38(12):838-44. PubMed ID: 17163361
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats.
Li XG; Li L; Zhou X; Chen Y; Ren YP; Zhou TY; Lu W
Acta Pharmacol Sin; 2012 Nov; 33(11):1379-86. PubMed ID: 22659626
[TBL] [Abstract][Full Text] [Related]
25. The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Thazhath SS; Marathe CS; Wu T; Chang J; Khoo J; Kuo P; Checklin HL; Bound MJ; Rigda RS; Crouch B; Jones KL; Horowitz M; Rayner CK
Diabetes; 2016 Jan; 65(1):269-75. PubMed ID: 26470783
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
[TBL] [Abstract][Full Text] [Related]
27. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.
Ghofaili KA; Fung M; Ao Z; Meloche M; Shapiro RJ; Warnock GL; Elahi D; Meneilly GS; Thompson DM
Transplantation; 2007 Jan; 83(1):24-8. PubMed ID: 17220786
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study.
Gu N; Cho SH; Kim J; Shin D; Seol E; Lee H; Lim KS; Shin SG; Jang IJ; Yu KS
Clin Ther; 2014 Jan; 36(1):101-14. PubMed ID: 24373998
[TBL] [Abstract][Full Text] [Related]
29. Exenatide Is an Effective Antihyperglycaemic Agent in a Mouse Model of Wolfram Syndrome 1.
Sedman T; Rünkorg K; Krass M; Luuk H; Plaas M; Vasar E; Volke V
J Diabetes Res; 2016; 2016():9239530. PubMed ID: 27069934
[TBL] [Abstract][Full Text] [Related]
30. Assessment of the effects of epinephrine and insulin on plasma and serum biochemical variables in llamas and alpacas.
Cebra CK; Tornquist SJ
Am J Vet Res; 2004 Dec; 65(12):1692-6. PubMed ID: 15631035
[TBL] [Abstract][Full Text] [Related]
31. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of insulin secretion and action in New World camelids.
Firshman AM; Cebra CK; Schanbacher BJ; Seaquist ER
Am J Vet Res; 2013 Jan; 74(1):96-101. PubMed ID: 23270352
[TBL] [Abstract][Full Text] [Related]
33. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1.
Parkes DG; Mace KF; Trautmann ME
Expert Opin Drug Discov; 2013 Feb; 8(2):219-44. PubMed ID: 23231438
[TBL] [Abstract][Full Text] [Related]
34. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
[TBL] [Abstract][Full Text] [Related]
35. Exenatide: a novel approach for treatment of type 2 diabetes.
Mikhail N
South Med J; 2006 Nov; 99(11):1271-9. PubMed ID: 17195423
[TBL] [Abstract][Full Text] [Related]
36. Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog.
Edgerton DS; An Z; Johnson KM; Farmer T; Farmer B; Neal D; Cherrington AD
Am J Physiol Endocrinol Metab; 2013 Jul; 305(1):E132-9. PubMed ID: 23673158
[TBL] [Abstract][Full Text] [Related]
37. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Ciccarelli L; D'Angelo A; Fogari E; Maffioli P
Can J Physiol Pharmacol; 2013 Sep; 91(9):724-32. PubMed ID: 23984793
[TBL] [Abstract][Full Text] [Related]
38. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
[TBL] [Abstract][Full Text] [Related]
39. Model-Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion.
Cirincione B; LaCreta F; Sager P; Mager DE
J Clin Pharmacol; 2017 Aug; 57(8):956-965. PubMed ID: 28543393
[TBL] [Abstract][Full Text] [Related]
40. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
Kolterman OG; Buse JB; Fineman MS; Gaines E; Heintz S; Bicsak TA; Taylor K; Kim D; Aisporna M; Wang Y; Baron AD
J Clin Endocrinol Metab; 2003 Jul; 88(7):3082-9. PubMed ID: 12843147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
